Evidence map›Paper›PMID 21547483›Full record

ReviewInternal and emergency medicine2011

Retinal vein occlusions: a review for the internist.

Rossella Marcucci, Francesco Sofi, Elisa Grifoni, Andrea Sodi, Domenico Prisco

Abstract readReview
PubMed Publisher
In one paragraph

Review in Internal and emergency medicine, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.

0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed
4.3field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

27 citing papers in PubMed, 62 citations in OpenAlex.

  1. Trial
  2. Retinal vascular occlusions in COVID-19 infection and vaccination: a literature review.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2023
    Review
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. ABO blood groups and the risk of retinal vein occlusion.Internal and emergency medicine · 2021
    Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Individual benefits of enoxaparin treatment in branch vein occlusion.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2018
    Article
  15. A Review on the Extraction of Quantitative Retinal Microvascular Image Feature.Computational and mathematical methods in medicine · 2018
    Review
  16. [Multiple thrombophilic risk markers in patients ≺65 years of age with retinal vein occlusion].Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft · 2017
    Article
  17. Guidance for the management of venous thrombosis in unusual sites.Journal of thrombosis and thrombolysis · 2016
    Review
  18. Article
  19. Article
  20. [Cardiovascular and hemostaseological view of retinal vascular occlusions].Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft · 2014
    Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Rossella MarcucciDepartment of Medical and Surgical Critical Area, University of Florence, Florence, Italy. r.marcucci@dac.unifi.it
Francesco Sofi
Elisa Grifoni
Andrea Sodi
Domenico Prisco
University of Florence · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Retinal vein occlusion (RVO) is a disease that is often associated with a variety of systemic disorders including arterial hypertension, diabetes mellitus, dyslipidemia and systemic vasculitis. There are various types of RVO, categorized on the basis of the site of occlusion and on the type of consequent vascular damage. Central retinal vein occlusion (CRVO) is the most clinically relevant type of RVO. In addition to well-known classical risk factors, new thrombophilic factors have been investigated in patients with RVO. Data concerning a number of the parameters remain contradictory; yet, hyperhomocysteinemia and vitamins involved in methionine metabolism appear to play a significant role in the pathogenesis of this disease. Alterations in the fibrinolysis pathway (elevated levels of PAI-1 and Lipoprotein (a)), together with haemorheologic modifications have been recently consistently associated with the disease. Medical treatment includes identification and correction of vascular risk factors. In addition, LMWHs appear to be the best therapeutic approach even if based on a limited number of trials, conducted on a limited number of patients. No data are available on the possible role of antithrombotic strategies in the long-term prevention of recurrent RVO or vascular events.

Indexed as

FibrinolysisFluorescein AngiographyHeparin, Low-Molecular-WeightHumansInternal MedicineRetinal VeinRetinal Vein OcclusionRisk FactorsTomography, Optical CoherenceHeparin, Low-Molecular-Weight

Identifiers

PMID21547483
OpenAlexW2050576350

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.